Active — Not RecruitingNot Applicable

A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan

Romania500 participantsStarted 2026-01-28

Plain-language summary

The aim of this study is to describe the real-world clinical profile, treatment patterns, and guideline alignment of patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan in routine clinical practice in Romania. The study uses secondary use of data, with all analyses conducted on anonymized, pre-existing data collected for routine clinical and administrative purposes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * A recorded diagnosis of HFrEF. * At least one prescription of sacubitril/valsartan during the identification period. * Age ≥18 years at the index date. Exclusion criteria: • Patients who do not meet inclusion criteria.

What they're measuring

Percentage of Patients Receiving all Four Guideline-recommended Therapeutic Classes for HFrEF

Timeframe: Up to approximately 5 years and 6 months

Trial details

NCT IDNCT07465679

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-03-31

View on ClinicalTrials.gov More Heart Failure With Reduced Ejection Fraction trials